Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month price objectives for Kiniksa Pharmaceuticals' stock. Their KNSA share price forecasts range from $34.00 to $34.00. On average, they anticipate the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 104.0% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.

Kiniksa Pharmaceuticals' stock was trading at $11.77 at the beginning of 2022. Since then, KNSA stock has increased by 41.6% and is now trading at $16.67.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our KNSA earnings forecast.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its quarterly earnings results on Monday, November, 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 80.53% and a negative trailing twelve-month return on equity of 15.66%.

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.22%), Vanguard Group Inc. (4.43%), Pictet Asset Management SA (4.37%), Rubric Capital Management LP (2.08%), Rice Hall James & Associates LLC (1.08%) and State Street Corp (0.88%). Insiders that own company stock include Barry D Quart, John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends.

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KNSA stock can currently be purchased for approximately $16.67.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $1.16 billion and generates $38.54 million in revenue each year. The company earns $-157,920,000.00 in net income (profit) each year or $2.00 on an earnings per share basis.

The company employs 215 workers across the globe.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at 448081896257 or via email at ir@kiniksa.com.